iron dextran / Generic mfg. - LARVOL DELTA

Baicalein Alleviates Iron Overload-Induced Ferroptosis and Osteogenic Blockade in Osteoblasts by Activating the Nrf2/GPX4 Pathway. (PubMed, BME Front) - " Using iron dextran-treated MC3T3-E1 osteoblasts and a murine iron overload model, we assessed the effects of baicalein on cell viability, osteogenic differentiation, ferroptosis markers, and the nuclear factor erythroid 2-related factor 2 (Nrf2)/glutathione peroxidase 4 (GPX4) pathway via biochemical assays, Western blot, and micro-computed tomography...In mice, baicalein reduced iron deposition, oxidative stress, and bone loss, and these effects were abolished by Nrf2 inhibition. Baicalein alleviates iron overload-induced osteoblast ferroptosis and osteoporosis by activating the Nrf2/GPX4 pathway, supporting its clinical potential as a therapeutic agent for iron-related bone disorders."

Journal • Hematological Disorders • Orthopedics • Osteoporosis • Rheumatology • GPX4 • SLC7A11

Impact of iron dextran shortage on patients with intestinal failure receiving home parenteral nutrition: Experience from a multidisciplinary rehabilitation program. (PubMed, Intest Fail) - "Given the association of iron deficiency with neurocognitive deficits, management of iron status should focus on prevention of iron deficiency. Therefore, for patients with IF on long-term PN, iron can be beneficial as part of the PN prescription for adequate provision of a balance nutrient profile."

Journal • Cognitive Disorders • Hematological Disorders • Pediatrics

Effect of Intravenous Iron Dextran on Kidney Outcomes in Acute Kidney Injury with Iron Deficiency: A Randomized Trial. (PubMed, Kidney360) - "In patients with AKI and iron deficiency, a single dose of IV iron, compared to usual care, did not improve clinical outcomes evaluated by MAKE90, the hemoglobin value, but was safe."

Journal • Acute Kidney Injury • Hematological Disorders • Nephrology • Renal Disease

Evaluation of the protective effect of the Echinacea Purpurea against apoptosis and inflammation induced by overdose of iron dextran on the hematopoietic system. (PubMed, J Complement Integr Med) - "Echinacea Purpurea exhibits anti-inflammatory and immunomodulatory effects, and it reduces bone marrow suppression and spleen cell injury caused by iron overload."

Journal • Hematological Disorders • Inflammation • AKT1 • FASLG • IL6 • NFKB1 • SIRT3

Cost-Effectiveness of First-Line IV Versus Oral Iron for Iron Deficiency Anemia in Women with Heavy Menstrual Bleeding. (PubMed, Blood Adv) - "We developed a Markov model simulating a cohort of women from age 18 to 51, comparing first-line treatment with IV iron dextran, IV ferumoxytol, IV iron sucrose, or oral ferrous sulfate. Our findings indicate that first-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds. These results support expanding access to IV iron as a first-line option and highlight the need to reduce treatment delays and insurance-related barriers."

HEOR • Journal • Anemia • Hematological Disorders

Parenteral replacement therapy with iron dextran or ferumoxytol in patients with iron deficiency. (PubMed, Int J Clin Pharmacol Ther) - "In patients with iron deficiency, the change of the hematological parameters after replacement therapy was not statistically different between iron dextran and ferumoxytol. Our data suggests that these two formulations have similar efficacy and safety after the IV administration of equivalent doses."

Journal • Hematological Disorders

Darbepoetin plus slow-release IntraVenous Iron to decrease transfusions and improve iron status and neurodevelopment in preterm infants (DIVI): study protocol for a randomized, blinded phase II trial. (PubMed, Trials) - P2 | "This trial will determine whether darbepoetin plus a slow-release IV iron preparation is safe, which iron preparation and dose best maintain iron sufficiency and decrease or eliminate transfusions, whether IV iron will result in a more diverse, less pathogenic microbiome when compared to oral iron supplementation, and, finally, whether these treatments affect neurodevelopment to 2 years corrected age."

Journal • P2 data • Critical care • Hematological Disorders

Real world evidence of treatment patterns in hereditary hemorrhagic telangiectasia (ASH 2025) - "Treatment examinedincluded bevacizumab, pazopanib, pomalidomide, aminocaproate, tranexamic acid (TXA), octreotide,lanreotide, thalidomide, tacrolimus, sirolimus, tamoxifen and raloxifene...The majority of HHT patients were treated withferrous sulfate (n=910), followed by iron sucrose, ferrous gluconate, ferric carboxymaltose, iron dextran,and ferric derisomaltose...While 8% of patients treated with TXA had VTE, the data does not support a definitiveconclusion of increased VTE in patients treated with anti-fibrinolytics. To further elucidate treatmentpractices in HHT, a multi-center approach incorporating review of medical records would providevaluable insights into real-world practices."

Clinical • HEOR • Real-world • Real-world evidence • Anemia • Aplastic Anemia • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Disorder • Hematological Disorders • Hypertension • Renal Disease • Venous Thromboembolism

Optimizing the Administration of Iron Dextran (ASHP 2025) - No abstract available

Testing 1, 2, 3: Does Iron Dextran Require a Test Dose? (ASHP 2025) - "Learning Objectives: Summarize the evidence refuting the need for a test dose prior to iron dextran administration."

Safety Outcomes of Intravenous Iron Therapies: Low Molecular Weight Iron Dextran versus Non-Dextran Iron Products (ASHP 2025) - No abstract available

Clinical

Integration of Proteomics, Network Pharmacology and Mendelian Randomization: Revealing Key Targets and Mechanisms of Huoluo Xiaoling Pellet in Improving Knee Osteoarthritis. (PubMed, J Ethnopharmacol) - "This study is the first to demonstrate that HXP and its bioactive compound Sal B, can intervene in the vicious cycle of "oxidative stress-iron metabolism disorder-energy dysfunction-inflammation " through multiple pathways. They regulate chondrocyte metabolic reprogramming, ameliorate KOA, and alleviate systemic iron metabolism disorders. From the perspective of material exchange and energy metabolism, this provides a modern scientific basis for the prevention and treatment of KOA by the TCM theory of "activating blood circulation and dredging collaterals"."

Journal • Cardiovascular • Immunology • Inflammation • Metabolic Disorders • Orthopedics • Osteoarthritis • Pain • Rheumatology • GPX4 • NCOA4

Parental replacement therapy with iron dextran or ferumoxytol in patients with iron defiency (ASH 2025) - "In patients with iron deficiency, the change of the hematological parameters after replacement therapy was not statistically different between iron dextran and ferumoxytol. Our data suggests that these two formulations have similar efficacy and safety after the IV administration of a single dose of 1,020 mg."

Clinical • Hematological Disorders

Cost analysis compared with efficacy shows iron dextran surpassing other intravenous iron formulations in children: A tertiary children's hospital experience (ASH 2025) - "Overall, IDx may be the preferred IVI formulation inchildren based on our center's experience. Future multi-center studies are needed to confirm our results."

Clinical • Cost-analysis • HEOR • Hematological Disorders

High versus low-cost intravenous iron in Medicare: Utilization patterns of iron infusions in traditional fee-for-service Medicare and Medicare advantage for iron deficiency anemia (ASH 2025) - "The mostcommon infusions were iron sucrose (43%), ferric carboxymaltose (23%), ferumoxytol (18%), iron dextran(8%), ferric gluconate (6%) and derisomaltose (1%). This could be due to incentivedifferences offered by various plan structures in MA relative to TM. Future research should assess thedownstream implications of these patterns overtime, on outcomes and on cost-effectiveness."

Medicare • Reimbursement • US reimbursement • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort (ASH 2025) - "Statistical analysis was performed usingWilcoxon signed-rank test for paired analysis of pre/post treatment labs, Kruskal-Wallis test as well aslinear mixed model for comparison of Hgb/ferritin improvement across IVI formulations, and Chi-squareanalysis as well as logistic mixed model for comparison of adverse effects.Results Our study included 344 patients, receiving a total of 661 IVI treatments [237(35.9%) iron sucrose (IS),226(34.2%) iron dextran (IDx), 155(23.4%) ferric carboxymaltose (FCM), 41(6.2%) ferric gluconate (FG),2(0.3%) ferumoxytol (FM)]. Limitations of this study include its retrospective nature and potentialselection bias. Prospective studies in children are needed to validate our findings."

Clinical • Celiac Disease • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immunology • Inflammation • Inflammatory Bowel Disease • Nephrology • Pediatrics

A quality improvement project to improve the delivery rate of IV iron to patients admitted with severe gastrointestinal hemorrhage (ASH 2025) - "An increase in the proportion of IV iron dextran utilization was seen over the course of thisquality improvement project; however, the proportion of patients being treated with IV iron was relativelystable. Subsequent PDSA cycles should focus on clinical care pathways and electronic medical recordalerts to more reliably identify patients at risk of ID who could benefit from IV iron therapy prior todischarge."

Clinical • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hematological Disorders • Renal Disease

Therapeutic effects of Tmprss6 suppression are negated by iron overload in a mouse model of beta-thalassemia (ASH 2025) - "C57BL/6 mice were either treatedwith 10 mg of i.p. iron dextran prior to the previously described Tmprss6 ASO treatment or placed on5000 ppm high iron diet throughout the duration of the Tmprss6 ASO treatment...Neither serum and tissue iron, nor CBCs were altered in thesehigh iron groups after Tmprss6 inhibition.Overall, we have demonstrated that while Tmprss6 inhibition is effective in increasing hepcidin andimproving thalassemia under usual iron-replete conditions, its effect is blunted in the presence of moresevere iron overload caused by either high ERFE concentrations or by the administration of exogenousiron. Similar factors may make patients with beta-thalassemia resistant to treatments targeting Tmprss6."

Preclinical • Anemia • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • ERFE • HAMP • TMPRSS6

Raising the bar in maternofetal hematology: Cost-effectiveness of iron deficiency screening in pregnancy across ferritin-based thresholds (ASH 2025) - "If found to be iron deficient, patientswere treated with a single dose of 1g intravenous iron dextran... The identification and treatment of ID beginning in the second trimester at a ferritinthreshold of <30µg/L is the cost-effective intervention, in comparison to a threshold of <15µg/L or noscreening. These results fill a critical gap in maternofetal medicine and may help inform the forthcomingAmerican Society of Hematology Clinical Practice Guidelines on the Diagnosis and Treatment of IronDeficiency."

Cost effectiveness • HEOR • Hematological Disorders • Postpartum Hemorrhage

Implementation of a multidisciplinary quality improvement project standardizing an approach to screening and treating iron deficiency in pregnancy (ASH 2025) - "ID in pregnancy is underrecognized and undertreated. Through a multidisciplinary QIinitiative, screening for ID improved from 10% to over 60% of pregnancies within one year of projectinitiation. Over the same period, there was a 20-fold increase in the number of IV iron dextran infusionsresulting in an increase in median hemoglobin by over 1 g/dL and a signal for decreased transfusionrequirements."

Anesthesia • Hematological Disorders • Obstetrics

Additional intramuscular iron injections tended to improve post-weaning growth when administered at weaning, but not at day seven of life. (PubMed, Transl Anim Sci) - "A total of 440 mixed sex pigs were used in this experiment in three treatment groups: control: only receiving iron dextran two days after birth; day 7: receiving iron injections at days two and seven after birth; Weaning iron: receiving iron dextran injections on day two and at weaning (20.1 days)...Plasma hepcidin anti-microbial peptide, was elevated in the weaning iron group after injection, possibly impairing enteric iron absorption. An additional injection at weaning showed potential for improved growth in the post-weaning period and has practical advantages for producers."

Journal • Hematological Disorders

Economic evaluation of intravenous iron formulations for patients with iron deficiency anemia: a systematic review. (PubMed, Front Health Serv) - "Six studies compared ferric carboxymaltose (FCM) with iron sucrose (IS); two studies compared FCM, ferric derisomaltose (FDI), and IS; one study compared FCM, iron dextran (ID), and IS; one study compared FCM, IS, ID, and FDI at three dose levels; one study obtained an economic ranking for FCM, ID, IS, and ferrous gluconate (FG); five studies compared FDI and FCM; and one study compared FDI with IS...Current evidence suggests that the efficacy of FDI is better than IS, and the economic ranking of the four intravenous iron formulations can be summarized as FCM, ID, IS, and FG. Further research is needed to justify the economic comparison between FCM and FDI."

HEOR • Journal • Review • Anemia • Hematological Disorders

DIVI: Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: University of Washington | Trial completion date: Dec 2027 ➔ Jun 2027 | Trial primary completion date: Dec 2025 ➔ Oct 2026

Trial completion date • Trial primary completion date • Anemia • Hematological Disorders

Iron dextran nanoparticles interacting with micrometric crosslinked protein scaffolds: Theoretical, computational and experimental results to design formulations for iron deficiency. (PubMed, Int J Biol Macromol) - "This is the first time that theoretical, computational and experimental studies were applied to IDN, multiple IDN and interactions with MCGS. These tools could be used for other protein scaffolds to predict drug encapsulation and delivery."

Journal • Hematological Disorders

Administration of green tea polyphenols mitigates iron-overload-induced bone loss in a β-thalassemia mouse model. (PubMed, NPJ Sci Food) - "This study assessed the effects of GTE on bone health in β-thalassemia knockout mice subjected to 4 weeks of iron dextran injections, followed by 2 months of daily oral treatment with deionized water, deferiprone (50 mg/kg), GTE (50 mg EGCG/kg), the combination of deferiprone and GTE, EGCG (50 mg/kg), or vitamin D3 (0.5 μg/kg ). GTE treatment reduced systemic iron burden, malondialdehyde, alkaline phosphatase, and parathyroid hormone, while improving femoral microarchitecture, bone mineral density, plasma calcium, and bone morphogenetic protein expression. These findings suggest GTE protects against iron-induced bone loss through combined chelation and antioxidation, supporting its potential as a therapeutic strategy."

Journal • Preclinical • Beta-Thalassemia • Genetic Disorders • Hematological Disorders • Osteoporosis • Rheumatology